nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosutinib—CSF1R—atherosclerosis	0.451	1	CbGaD
Bosutinib—STK10—renal artery—atherosclerosis	0.00553	0.0426	CbGeAlD
Bosutinib—ABCB1—Ezetimibe—atherosclerosis	0.005	0.152	CbGbCtD
Bosutinib—ABCB1—Simvastatin—atherosclerosis	0.00465	0.141	CbGbCtD
Bosutinib—ABCB1—Pravastatin—atherosclerosis	0.00455	0.138	CbGbCtD
Bosutinib—ABCB1—Lovastatin—atherosclerosis	0.00455	0.138	CbGbCtD
Bosutinib—CYP3A4—Ezetimibe—atherosclerosis	0.00299	0.0909	CbGbCtD
Bosutinib—CYP3A4—Rosuvastatin—atherosclerosis	0.00299	0.0909	CbGbCtD
Bosutinib—CYP3A4—Simvastatin—atherosclerosis	0.00278	0.0845	CbGbCtD
Bosutinib—CYP3A4—Pravastatin—atherosclerosis	0.00272	0.0827	CbGbCtD
Bosutinib—CYP3A4—Lovastatin—atherosclerosis	0.00272	0.0827	CbGbCtD
Bosutinib—CASK—Pitavastatin—Rosuvastatin—atherosclerosis	0.00255	0.697	CbGdCrCtD
Bosutinib—RPS6KB1—leg—atherosclerosis	0.00238	0.0183	CbGeAlD
Bosutinib—Blood creatine phosphokinase increased—Rosuvastatin—atherosclerosis	0.00226	0.0181	CcSEcCtD
Bosutinib—RPS6KB1—hindlimb—atherosclerosis	0.00212	0.0164	CbGeAlD
Bosutinib—Blood creatine phosphokinase increased—Lovastatin—atherosclerosis	0.00191	0.0153	CcSEcCtD
Bosutinib—Blood creatine phosphokinase increased—Ezetimibe—atherosclerosis	0.00188	0.015	CcSEcCtD
Bosutinib—RPS6KB1—appendage—atherosclerosis	0.00182	0.014	CbGeAlD
Bosutinib—Blood creatine phosphokinase increased—Simvastatin—atherosclerosis	0.00179	0.0143	CcSEcCtD
Bosutinib—Respiratory tract infection—Pravastatin—atherosclerosis	0.00177	0.0142	CcSEcCtD
Bosutinib—BMPR2—artery—atherosclerosis	0.0017	0.0131	CbGeAlD
Bosutinib—Blood creatine phosphokinase increased—Pravastatin—atherosclerosis	0.00162	0.013	CcSEcCtD
Bosutinib—Gamma-glutamyltransferase increased—Ezetimibe—atherosclerosis	0.00157	0.0126	CcSEcCtD
Bosutinib—Hepatotoxicity—Niacin—atherosclerosis	0.00146	0.0117	CcSEcCtD
Bosutinib—Vandetanib—VEGFA—atherosclerosis	0.00142	0.656	CrCbGaD
Bosutinib—Gamma-glutamyltransferase increased—Pravastatin—atherosclerosis	0.00135	0.0108	CcSEcCtD
Bosutinib—BMPR2—blood vessel—atherosclerosis	0.00133	0.0102	CbGeAlD
Bosutinib—Renal failure acute—Rosuvastatin—atherosclerosis	0.00122	0.00978	CcSEcCtD
Bosutinib—PTK2—endothelium—atherosclerosis	0.00114	0.00882	CbGeAlD
Bosutinib—CHEK2—Pitavastatin—Rosuvastatin—atherosclerosis	0.00111	0.303	CbGdCrCtD
Bosutinib—SIK2—connective tissue—atherosclerosis	0.0011	0.00848	CbGeAlD
Bosutinib—Hepatic function abnormal—Lovastatin—atherosclerosis	0.00109	0.00875	CcSEcCtD
Bosutinib—Fluid retention—Niacin—atherosclerosis	0.00107	0.00859	CcSEcCtD
Bosutinib—PTK2—blood vessel—atherosclerosis	0.00105	0.00813	CbGeAlD
Bosutinib—SRC—artery—atherosclerosis	0.00105	0.00808	CbGeAlD
Bosutinib—EPHB4—endothelium—atherosclerosis	0.00104	0.00802	CbGeAlD
Bosutinib—Rash maculo-papular—Niacin—atherosclerosis	0.00103	0.00823	CcSEcCtD
Bosutinib—Hepatic function abnormal—Simvastatin—atherosclerosis	0.00102	0.00819	CcSEcCtD
Bosutinib—SRMS—connective tissue—atherosclerosis	0.001	0.00771	CbGeAlD
Bosutinib—Influenza—Rosuvastatin—atherosclerosis	0.000974	0.0078	CcSEcCtD
Bosutinib—SYK—connective tissue—atherosclerosis	0.000961	0.00741	CbGeAlD
Bosutinib—EPHB4—blood vessel—atherosclerosis	0.00096	0.0074	CbGeAlD
Bosutinib—CDK2—connective tissue—atherosclerosis	0.000952	0.00734	CbGeAlD
Bosutinib—EPHA2—blood vessel—atherosclerosis	0.000942	0.00726	CbGeAlD
Bosutinib—Hepatic function abnormal—Niacin—atherosclerosis	0.000939	0.00752	CcSEcCtD
Bosutinib—Bronchitis—Rosuvastatin—atherosclerosis	0.000937	0.0075	CcSEcCtD
Bosutinib—Hepatic function abnormal—Pravastatin—atherosclerosis	0.000924	0.0074	CcSEcCtD
Bosutinib—BMX—cardiovascular system—atherosclerosis	0.00091	0.00702	CbGeAlD
Bosutinib—PHKG1—cardiovascular system—atherosclerosis	0.00089	0.00686	CbGeAlD
Bosutinib—SRC—endothelium—atherosclerosis	0.000885	0.00682	CbGeAlD
Bosutinib—Renal failure acute—Pravastatin—atherosclerosis	0.000875	0.00701	CcSEcCtD
Bosutinib—TLK1—adipose tissue—atherosclerosis	0.000868	0.00669	CbGeAlD
Bosutinib—PRKCQ—adipose tissue—atherosclerosis	0.000855	0.00659	CbGeAlD
Bosutinib—SIK2—adipose tissue—atherosclerosis	0.000844	0.00651	CbGeAlD
Bosutinib—Aspartate aminotransferase increased—Ezetimibe—atherosclerosis	0.000844	0.00676	CcSEcCtD
Bosutinib—PLK2—connective tissue—atherosclerosis	0.000839	0.00647	CbGeAlD
Bosutinib—Nasopharyngitis—Ezetimibe—atherosclerosis	0.000838	0.00671	CcSEcCtD
Bosutinib—Gastritis—Ezetimibe—atherosclerosis	0.000829	0.00664	CcSEcCtD
Bosutinib—CDK2—cardiovascular system—atherosclerosis	0.000829	0.00639	CbGeAlD
Bosutinib—Alanine aminotransferase increased—Ezetimibe—atherosclerosis	0.000826	0.00662	CcSEcCtD
Bosutinib—Influenza—Lovastatin—atherosclerosis	0.000826	0.00661	CcSEcCtD
Bosutinib—Hepatobiliary disease—Rosuvastatin—atherosclerosis	0.000821	0.00658	CcSEcCtD
Bosutinib—Gastrointestinal haemorrhage—Niacin—atherosclerosis	0.00082	0.00657	CcSEcCtD
Bosutinib—SRC—blood vessel—atherosclerosis	0.000816	0.00629	CbGeAlD
Bosutinib—Influenza—Ezetimibe—atherosclerosis	0.00081	0.00649	CcSEcCtD
Bosutinib—DSTYK—adipose tissue—atherosclerosis	0.000803	0.00619	CbGeAlD
Bosutinib—BMX—adipose tissue—atherosclerosis	0.000803	0.00619	CbGeAlD
Bosutinib—CLK3—adipose tissue—atherosclerosis	0.000803	0.00619	CbGeAlD
Bosutinib—STK4—connective tissue—atherosclerosis	0.000802	0.00619	CbGeAlD
Bosutinib—Face oedema—Niacin—atherosclerosis	0.000792	0.00634	CcSEcCtD
Bosutinib—Abdominal discomfort—Lovastatin—atherosclerosis	0.000791	0.00634	CcSEcCtD
Bosutinib—Gastritis—Simvastatin—atherosclerosis	0.000791	0.00633	CcSEcCtD
Bosutinib—WEE1—cardiovascular system—atherosclerosis	0.000786	0.00606	CbGeAlD
Bosutinib—DMPK—cardiovascular system—atherosclerosis	0.000786	0.00606	CbGeAlD
Bosutinib—CASK—adipose tissue—atherosclerosis	0.000785	0.00605	CbGeAlD
Bosutinib—Hepatitis—Rosuvastatin—atherosclerosis	0.00078	0.00625	CcSEcCtD
Bosutinib—EIF2AK1—adipose tissue—atherosclerosis	0.000776	0.00598	CbGeAlD
Bosutinib—TYRO3—connective tissue—atherosclerosis	0.000758	0.00585	CbGeAlD
Bosutinib—ALK—connective tissue—atherosclerosis	0.000758	0.00585	CbGeAlD
Bosutinib—LYN—connective tissue—atherosclerosis	0.000754	0.00582	CbGeAlD
Bosutinib—Upper respiratory tract infection—Ezetimibe—atherosclerosis	0.000753	0.00603	CcSEcCtD
Bosutinib—FES—adipose tissue—atherosclerosis	0.000752	0.0058	CbGeAlD
Bosutinib—VRK2—adipose tissue—atherosclerosis	0.000752	0.0058	CbGeAlD
Bosutinib—Bronchitis—Simvastatin—atherosclerosis	0.000743	0.00595	CcSEcCtD
Bosutinib—Abdominal discomfort—Simvastatin—atherosclerosis	0.00074	0.00593	CcSEcCtD
Bosutinib—BTK—connective tissue—atherosclerosis	0.000739	0.0057	CbGeAlD
Bosutinib—SYK—adipose tissue—atherosclerosis	0.000738	0.00569	CbGeAlD
Bosutinib—CDK2—adipose tissue—atherosclerosis	0.000731	0.00563	CbGeAlD
Bosutinib—PLK2—cardiovascular system—atherosclerosis	0.00073	0.00563	CbGeAlD
Bosutinib—STK26—adipose tissue—atherosclerosis	0.000724	0.00558	CbGeAlD
Bosutinib—Nasopharyngitis—Pravastatin—atherosclerosis	0.000722	0.00579	CcSEcCtD
Bosutinib—Infestation NOS—Ezetimibe—atherosclerosis	0.000722	0.00578	CcSEcCtD
Bosutinib—Infestation—Ezetimibe—atherosclerosis	0.000722	0.00578	CcSEcCtD
Bosutinib—Upper respiratory tract infection—Simvastatin—atherosclerosis	0.000718	0.00575	CcSEcCtD
Bosutinib—Alanine aminotransferase increased—Pravastatin—atherosclerosis	0.000712	0.00571	CcSEcCtD
Bosutinib—Influenza—Niacin—atherosclerosis	0.000709	0.00568	CcSEcCtD
Bosutinib—ROCK1—connective tissue—atherosclerosis	0.0007	0.00539	CbGeAlD
Bosutinib—CHEK2—adipose tissue—atherosclerosis	0.000699	0.00539	CbGeAlD
Bosutinib—Influenza—Pravastatin—atherosclerosis	0.000698	0.00559	CcSEcCtD
Bosutinib—DMPK—adipose tissue—atherosclerosis	0.000694	0.00535	CbGeAlD
Bosutinib—WEE1—adipose tissue—atherosclerosis	0.000694	0.00535	CbGeAlD
Bosutinib—Hepatobiliary disease—Ezetimibe—atherosclerosis	0.000683	0.00547	CcSEcCtD
Bosutinib—Bronchitis—Niacin—atherosclerosis	0.000682	0.00546	CcSEcCtD
Bosutinib—BMPR2—connective tissue—atherosclerosis	0.00068	0.00524	CbGeAlD
Bosutinib—STK25—adipose tissue—atherosclerosis	0.000662	0.0051	CbGeAlD
Bosutinib—Hepatitis—Lovastatin—atherosclerosis	0.000661	0.00529	CcSEcCtD
Bosutinib—EPHA3—adipose tissue—atherosclerosis	0.000657	0.00507	CbGeAlD
Bosutinib—MAP4K4—connective tissue—atherosclerosis	0.000654	0.00504	CbGeAlD
Bosutinib—PDGFRB—blood vessel—atherosclerosis	0.00065	0.00501	CbGeAlD
Bosutinib—Upper respiratory tract infection—Pravastatin—atherosclerosis	0.000649	0.0052	CcSEcCtD
Bosutinib—Hepatitis—Ezetimibe—atherosclerosis	0.000648	0.00519	CcSEcCtD
Bosutinib—PLK2—adipose tissue—atherosclerosis	0.000644	0.00496	CbGeAlD
Bosutinib—SIK3—adipose tissue—atherosclerosis	0.00064	0.00493	CbGeAlD
Bosutinib—Oedema peripheral—Ezetimibe—atherosclerosis	0.000639	0.00511	CcSEcCtD
Bosutinib—Connective tissue disorder—Ezetimibe—atherosclerosis	0.000637	0.0051	CcSEcCtD
Bosutinib—MAP2K1—connective tissue—atherosclerosis	0.000632	0.00487	CbGeAlD
Bosutinib—CSK—connective tissue—atherosclerosis	0.000628	0.00484	CbGeAlD
Bosutinib—Erythema multiforme—Lovastatin—atherosclerosis	0.000625	0.005	CcSEcCtD
Bosutinib—CLK1—connective tissue—atherosclerosis	0.00062	0.00478	CbGeAlD
Bosutinib—Hepatitis—Simvastatin—atherosclerosis	0.000618	0.00495	CcSEcCtD
Bosutinib—ERBB4—cardiovascular system—atherosclerosis	0.000617	0.00475	CbGeAlD
Bosutinib—STK4—adipose tissue—atherosclerosis	0.000616	0.00475	CbGeAlD
Bosutinib—Erythema multiforme—Ezetimibe—atherosclerosis	0.000613	0.00491	CcSEcCtD
Bosutinib—ROCK1—cardiovascular system—atherosclerosis	0.000609	0.00469	CbGeAlD
Bosutinib—TLK1—liver—atherosclerosis	0.000608	0.00469	CbGeAlD
Bosutinib—CAMK1D—adipose tissue—atherosclerosis	0.000608	0.00469	CbGeAlD
Bosutinib—BMP2K—connective tissue—atherosclerosis	0.000608	0.00469	CbGeAlD
Bosutinib—STK24—adipose tissue—atherosclerosis	0.000601	0.00464	CbGeAlD
Bosutinib—PRKCQ—liver—atherosclerosis	0.0006	0.00462	CbGeAlD
Bosutinib—Cough—Rosuvastatin—atherosclerosis	0.000592	0.00474	CcSEcCtD
Bosutinib—SIK2—liver—atherosclerosis	0.000592	0.00456	CbGeAlD
Bosutinib—BMPR2—cardiovascular system—atherosclerosis	0.000591	0.00456	CbGeAlD
Bosutinib—PTK2B—connective tissue—atherosclerosis	0.000587	0.00453	CbGeAlD
Bosutinib—Immune system disorder—Ezetimibe—atherosclerosis	0.000585	0.00469	CcSEcCtD
Bosutinib—Erythema multiforme—Simvastatin—atherosclerosis	0.000584	0.00468	CcSEcCtD
Bosutinib—Mediastinal disorder—Ezetimibe—atherosclerosis	0.000584	0.00468	CcSEcCtD
Bosutinib—FER—adipose tissue—atherosclerosis	0.000582	0.00449	CbGeAlD
Bosutinib—Arthralgia—Rosuvastatin—atherosclerosis	0.000578	0.00463	CcSEcCtD
Bosutinib—Myalgia—Rosuvastatin—atherosclerosis	0.000578	0.00463	CcSEcCtD
Bosutinib—FRK—liver—atherosclerosis	0.000577	0.00445	CbGeAlD
Bosutinib—MAP4K1—adipose tissue—atherosclerosis	0.00057	0.00439	CbGeAlD
Bosutinib—MAP4K4—cardiovascular system—atherosclerosis	0.000569	0.00439	CbGeAlD
Bosutinib—SIK1—connective tissue—atherosclerosis	0.000569	0.00438	CbGeAlD
Bosutinib—Hepatitis—Niacin—atherosclerosis	0.000568	0.00455	CcSEcCtD
Bosutinib—BTK—adipose tissue—atherosclerosis	0.000567	0.00437	CbGeAlD
Bosutinib—Malnutrition—Ezetimibe—atherosclerosis	0.000564	0.00452	CcSEcCtD
Bosutinib—Dysgeusia—Lovastatin—atherosclerosis	0.000563	0.00451	CcSEcCtD
Bosutinib—CLK3—liver—atherosclerosis	0.000563	0.00434	CbGeAlD
Bosutinib—Oedema peripheral—Niacin—atherosclerosis	0.000559	0.00448	CcSEcCtD
Bosutinib—TNK2—adipose tissue—atherosclerosis	0.000559	0.00431	CbGeAlD
Bosutinib—Hepatitis—Pravastatin—atherosclerosis	0.000559	0.00448	CcSEcCtD
Bosutinib—ERBB3—connective tissue—atherosclerosis	0.000558	0.0043	CbGeAlD
Bosutinib—Back pain—Lovastatin—atherosclerosis	0.000556	0.00446	CcSEcCtD
Bosutinib—MAP3K2—connective tissue—atherosclerosis	0.000552	0.00426	CbGeAlD
Bosutinib—MAP4K2—adipose tissue—atherosclerosis	0.000551	0.00425	CbGeAlD
Bosutinib—Infection—Rosuvastatin—atherosclerosis	0.00055	0.00441	CcSEcCtD
Bosutinib—CASK—liver—atherosclerosis	0.00055	0.00424	CbGeAlD
Bosutinib—MAP2K1—cardiovascular system—atherosclerosis	0.00055	0.00424	CbGeAlD
Bosutinib—CSK—cardiovascular system—atherosclerosis	0.000546	0.00421	CbGeAlD
Bosutinib—Back pain—Ezetimibe—atherosclerosis	0.000546	0.00437	CcSEcCtD
Bosutinib—EIF2AK1—liver—atherosclerosis	0.000544	0.0042	CbGeAlD
Bosutinib—ERBB4—adipose tissue—atherosclerosis	0.000544	0.00419	CbGeAlD
Bosutinib—STK3—adipose tissue—atherosclerosis	0.000544	0.00419	CbGeAlD
Bosutinib—Nervous system disorder—Rosuvastatin—atherosclerosis	0.000543	0.00435	CcSEcCtD
Bosutinib—CSNK1A1—cardiovascular system—atherosclerosis	0.000543	0.00418	CbGeAlD
Bosutinib—Thrombocytopenia—Rosuvastatin—atherosclerosis	0.000542	0.00434	CcSEcCtD
Bosutinib—PTK2—connective tissue—atherosclerosis	0.000541	0.00417	CbGeAlD
Bosutinib—CLK1—cardiovascular system—atherosclerosis	0.000539	0.00416	CbGeAlD
Bosutinib—Ill-defined disorder—Lovastatin—atherosclerosis	0.000534	0.00428	CcSEcCtD
Bosutinib—Tinnitus—Niacin—atherosclerosis	0.000529	0.00424	CcSEcCtD
Bosutinib—CAMK2G—cardiovascular system—atherosclerosis	0.000529	0.00408	CbGeAlD
Bosutinib—Erythema multiforme—Pravastatin—atherosclerosis	0.000528	0.00423	CcSEcCtD
Bosutinib—FES—liver—atherosclerosis	0.000528	0.00407	CbGeAlD
Bosutinib—VRK2—liver—atherosclerosis	0.000528	0.00407	CbGeAlD
Bosutinib—Dysgeusia—Simvastatin—atherosclerosis	0.000527	0.00422	CcSEcCtD
Bosutinib—Ill-defined disorder—Ezetimibe—atherosclerosis	0.000524	0.00419	CcSEcCtD
Bosutinib—Anaemia—Ezetimibe—atherosclerosis	0.000521	0.00418	CcSEcCtD
Bosutinib—BMPR2—adipose tissue—atherosclerosis	0.000521	0.00402	CbGeAlD
Bosutinib—Tinnitus—Pravastatin—atherosclerosis	0.000521	0.00417	CcSEcCtD
Bosutinib—RPS6KB1—connective tissue—atherosclerosis	0.00052	0.00401	CbGeAlD
Bosutinib—Malaise—Lovastatin—atherosclerosis	0.000519	0.00416	CcSEcCtD
Bosutinib—Cardiac disorder—Pravastatin—atherosclerosis	0.000519	0.00415	CcSEcCtD
Bosutinib—TNIK—liver—atherosclerosis	0.000517	0.00399	CbGeAlD
Bosutinib—STK36—adipose tissue—atherosclerosis	0.000517	0.00399	CbGeAlD
Bosutinib—AXL—connective tissue—atherosclerosis	0.000515	0.00397	CbGeAlD
Bosutinib—Leukopenia—Lovastatin—atherosclerosis	0.000515	0.00412	CcSEcCtD
Bosutinib—CDK2—liver—atherosclerosis	0.000512	0.00395	CbGeAlD
Bosutinib—MERTK—adipose tissue—atherosclerosis	0.000511	0.00394	CbGeAlD
Bosutinib—PTK2B—cardiovascular system—atherosclerosis	0.000511	0.00394	CbGeAlD
Bosutinib—Malaise—Ezetimibe—atherosclerosis	0.000509	0.00408	CcSEcCtD
Bosutinib—STK26—liver—atherosclerosis	0.000508	0.00391	CbGeAlD
Bosutinib—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.000505	0.00404	CcSEcCtD
Bosutinib—MAP4K4—adipose tissue—atherosclerosis	0.000502	0.00387	CbGeAlD
Bosutinib—Ill-defined disorder—Simvastatin—atherosclerosis	0.000499	0.004	CcSEcCtD
Bosutinib—BCR—adipose tissue—atherosclerosis	0.000498	0.00384	CbGeAlD
Bosutinib—NUAK2—adipose tissue—atherosclerosis	0.000498	0.00384	CbGeAlD
Bosutinib—Anaemia—Simvastatin—atherosclerosis	0.000497	0.00398	CcSEcCtD
Bosutinib—MAP3K12—adipose tissue—atherosclerosis	0.000495	0.00381	CbGeAlD
Bosutinib—Malnutrition—Niacin—atherosclerosis	0.000494	0.00396	CcSEcCtD
Bosutinib—Cough—Ezetimibe—atherosclerosis	0.000492	0.00394	CcSEcCtD
Bosutinib—EPHB4—connective tissue—atherosclerosis	0.000492	0.00379	CbGeAlD
Bosutinib—Myalgia—Lovastatin—atherosclerosis	0.00049	0.00392	CcSEcCtD
Bosutinib—Chest pain—Lovastatin—atherosclerosis	0.00049	0.00392	CcSEcCtD
Bosutinib—Arthralgia—Lovastatin—atherosclerosis	0.00049	0.00392	CcSEcCtD
Bosutinib—WEE1—liver—atherosclerosis	0.000486	0.00375	CbGeAlD
Bosutinib—DMPK—liver—atherosclerosis	0.000486	0.00375	CbGeAlD
Bosutinib—Malaise—Simvastatin—atherosclerosis	0.000485	0.00389	CcSEcCtD
Bosutinib—MAP2K1—adipose tissue—atherosclerosis	0.000485	0.00374	CbGeAlD
Bosutinib—STK35—adipose tissue—atherosclerosis	0.000485	0.00374	CbGeAlD
Bosutinib—MAP2K2—cardiovascular system—atherosclerosis	0.000484	0.00373	CbGeAlD
Bosutinib—Discomfort—Lovastatin—atherosclerosis	0.000484	0.00388	CcSEcCtD
Bosutinib—FYN—connective tissue—atherosclerosis	0.000482	0.00372	CbGeAlD
Bosutinib—Leukopenia—Simvastatin—atherosclerosis	0.000482	0.00386	CcSEcCtD
Bosutinib—CSK—adipose tissue—atherosclerosis	0.000482	0.00371	CbGeAlD
Bosutinib—Chest pain—Ezetimibe—atherosclerosis	0.00048	0.00385	CcSEcCtD
Bosutinib—Arthralgia—Ezetimibe—atherosclerosis	0.00048	0.00385	CcSEcCtD
Bosutinib—Myalgia—Ezetimibe—atherosclerosis	0.00048	0.00385	CcSEcCtD
Bosutinib—CSNK1A1—adipose tissue—atherosclerosis	0.000478	0.00369	CbGeAlD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.000477	0.00382	CcSEcCtD
Bosutinib—Dysgeusia—Pravastatin—atherosclerosis	0.000476	0.00382	CcSEcCtD
Bosutinib—HCK—adipose tissue—atherosclerosis	0.000475	0.00366	CbGeAlD
Bosutinib—CLK1—adipose tissue—atherosclerosis	0.000475	0.00366	CbGeAlD
Bosutinib—Discomfort—Ezetimibe—atherosclerosis	0.000475	0.0038	CcSEcCtD
Bosutinib—Pain—Rosuvastatin—atherosclerosis	0.000474	0.00379	CcSEcCtD
Bosutinib—ABL2—adipose tissue—atherosclerosis	0.000472	0.00364	CbGeAlD
Bosutinib—TBK1—cardiovascular system—atherosclerosis	0.000471	0.00363	CbGeAlD
Bosutinib—PTK2—cardiovascular system—atherosclerosis	0.000471	0.00363	CbGeAlD
Bosutinib—Anaphylactic shock—Lovastatin—atherosclerosis	0.000469	0.00376	CcSEcCtD
Bosutinib—CAMK2G—adipose tissue—atherosclerosis	0.000467	0.0036	CbGeAlD
Bosutinib—BMP2K—adipose tissue—atherosclerosis	0.000467	0.0036	CbGeAlD
Bosutinib—Infection—Lovastatin—atherosclerosis	0.000466	0.00374	CcSEcCtD
Bosutinib—STK25—liver—atherosclerosis	0.000464	0.00358	CbGeAlD
Bosutinib—LRRK2—adipose tissue—atherosclerosis	0.000462	0.00356	CbGeAlD
Bosutinib—EGFR—adipose tissue—atherosclerosis	0.000461	0.00355	CbGeAlD
Bosutinib—Anaphylactic shock—Ezetimibe—atherosclerosis	0.00046	0.00369	CcSEcCtD
Bosutinib—Thrombocytopenia—Lovastatin—atherosclerosis	0.00046	0.00368	CcSEcCtD
Bosutinib—Arthralgia—Simvastatin—atherosclerosis	0.000458	0.00367	CcSEcCtD
Bosutinib—Myalgia—Simvastatin—atherosclerosis	0.000458	0.00367	CcSEcCtD
Bosutinib—Chest pain—Simvastatin—atherosclerosis	0.000458	0.00367	CcSEcCtD
Bosutinib—Infection—Ezetimibe—atherosclerosis	0.000457	0.00366	CcSEcCtD
Bosutinib—Feeling abnormal—Rosuvastatin—atherosclerosis	0.000457	0.00366	CcSEcCtD
Bosutinib—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.000453	0.00363	CcSEcCtD
Bosutinib—RPS6KB1—cardiovascular system—atherosclerosis	0.000453	0.00349	CbGeAlD
Bosutinib—Discomfort—Simvastatin—atherosclerosis	0.000453	0.00363	CcSEcCtD
Bosutinib—Nervous system disorder—Ezetimibe—atherosclerosis	0.000452	0.00362	CcSEcCtD
Bosutinib—PLK2—liver—atherosclerosis	0.000452	0.00348	CbGeAlD
Bosutinib—Ill-defined disorder—Pravastatin—atherosclerosis	0.000451	0.00362	CcSEcCtD
Bosutinib—Thrombocytopenia—Ezetimibe—atherosclerosis	0.000451	0.00361	CcSEcCtD
Bosutinib—PTK2B—adipose tissue—atherosclerosis	0.000451	0.00347	CbGeAlD
Bosutinib—FGR—cardiovascular system—atherosclerosis	0.00045	0.00347	CbGeAlD
Bosutinib—Anaemia—Pravastatin—atherosclerosis	0.00045	0.0036	CcSEcCtD
Bosutinib—SIK3—liver—atherosclerosis	0.000449	0.00346	CbGeAlD
Bosutinib—AXL—cardiovascular system—atherosclerosis	0.000448	0.00345	CbGeAlD
Bosutinib—Skin disorder—Ezetimibe—atherosclerosis	0.000447	0.00358	CcSEcCtD
Bosutinib—CSNK1E—adipose tissue—atherosclerosis	0.000443	0.00342	CbGeAlD
Bosutinib—Leukopenia—Niacin—atherosclerosis	0.000442	0.00354	CcSEcCtD
Bosutinib—Urticaria—Rosuvastatin—atherosclerosis	0.00044	0.00353	CcSEcCtD
Bosutinib—Anaphylactic shock—Simvastatin—atherosclerosis	0.000439	0.00352	CcSEcCtD
Bosutinib—Oedema—Simvastatin—atherosclerosis	0.000439	0.00352	CcSEcCtD
Bosutinib—Malaise—Pravastatin—atherosclerosis	0.000439	0.00351	CcSEcCtD
Bosutinib—Abdominal pain—Rosuvastatin—atherosclerosis	0.000438	0.00351	CcSEcCtD
Bosutinib—SIK1—adipose tissue—atherosclerosis	0.000436	0.00336	CbGeAlD
Bosutinib—IRAK4—adipose tissue—atherosclerosis	0.000436	0.00336	CbGeAlD
Bosutinib—Infection—Simvastatin—atherosclerosis	0.000436	0.00349	CcSEcCtD
Bosutinib—Leukopenia—Pravastatin—atherosclerosis	0.000435	0.00349	CcSEcCtD
Bosutinib—YES1—connective tissue—atherosclerosis	0.000435	0.00335	CbGeAlD
Bosutinib—EPHA4—adipose tissue—atherosclerosis	0.000432	0.00333	CbGeAlD
Bosutinib—STK4—liver—atherosclerosis	0.000432	0.00333	CbGeAlD
Bosutinib—Cough—Niacin—atherosclerosis	0.000431	0.00345	CcSEcCtD
Bosutinib—Thrombocytopenia—Simvastatin—atherosclerosis	0.00043	0.00344	CcSEcCtD
Bosutinib—TAOK3—connective tissue—atherosclerosis	0.000429	0.00331	CbGeAlD
Bosutinib—EPHB4—cardiovascular system—atherosclerosis	0.000428	0.0033	CbGeAlD
Bosutinib—ERBB3—adipose tissue—atherosclerosis	0.000428	0.0033	CbGeAlD
Bosutinib—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.000428	0.00343	CcSEcCtD
Bosutinib—ULK3—adipose tissue—atherosclerosis	0.000427	0.00329	CbGeAlD
Bosutinib—MAP2K2—adipose tissue—atherosclerosis	0.000427	0.00329	CbGeAlD
Bosutinib—CAMK1D—liver—atherosclerosis	0.000427	0.00329	CbGeAlD
Bosutinib—Cough—Pravastatin—atherosclerosis	0.000424	0.0034	CcSEcCtD
Bosutinib—MAP3K2—adipose tissue—atherosclerosis	0.000424	0.00327	CbGeAlD
Bosutinib—STK24—liver—atherosclerosis	0.000422	0.00325	CbGeAlD
Bosutinib—Myalgia—Niacin—atherosclerosis	0.000421	0.00337	CcSEcCtD
Bosutinib—Arthralgia—Niacin—atherosclerosis	0.000421	0.00337	CcSEcCtD
Bosutinib—EPHA2—cardiovascular system—atherosclerosis	0.00042	0.00324	CbGeAlD
Bosutinib—MAP3K7—adipose tissue—atherosclerosis	0.00042	0.00324	CbGeAlD
Bosutinib—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.00042	0.00336	CcSEcCtD
Bosutinib—FYN—cardiovascular system—atherosclerosis	0.000419	0.00323	CbGeAlD
Bosutinib—Dyspnoea—Lovastatin—atherosclerosis	0.000419	0.00335	CcSEcCtD
Bosutinib—SRC—connective tissue—atherosclerosis	0.000418	0.00323	CbGeAlD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000418	0.00335	CcSEcCtD
Bosutinib—TBK1—adipose tissue—atherosclerosis	0.000415	0.0032	CbGeAlD
Bosutinib—PTK2—adipose tissue—atherosclerosis	0.000415	0.0032	CbGeAlD
Bosutinib—Arthralgia—Pravastatin—atherosclerosis	0.000414	0.00332	CcSEcCtD
Bosutinib—Chest pain—Pravastatin—atherosclerosis	0.000414	0.00332	CcSEcCtD
Bosutinib—Myalgia—Pravastatin—atherosclerosis	0.000414	0.00332	CcSEcCtD
Bosutinib—Dyspnoea—Ezetimibe—atherosclerosis	0.000411	0.00329	CcSEcCtD
Bosutinib—MAP3K3—cardiovascular system—atherosclerosis	0.00041	0.00316	CbGeAlD
Bosutinib—Discomfort—Pravastatin—atherosclerosis	0.000409	0.00328	CcSEcCtD
Bosutinib—Decreased appetite—Lovastatin—atherosclerosis	0.000408	0.00327	CcSEcCtD
Bosutinib—FER—liver—atherosclerosis	0.000408	0.00315	CbGeAlD
Bosutinib—IRAK1—adipose tissue—atherosclerosis	0.000407	0.00314	CbGeAlD
Bosutinib—LYN—liver—atherosclerosis	0.000406	0.00313	CbGeAlD
Bosutinib—Fatigue—Lovastatin—atherosclerosis	0.000405	0.00324	CcSEcCtD
Bosutinib—Oedema—Niacin—atherosclerosis	0.000403	0.00323	CcSEcCtD
Bosutinib—Anaphylactic shock—Niacin—atherosclerosis	0.000403	0.00323	CcSEcCtD
Bosutinib—Pain—Lovastatin—atherosclerosis	0.000401	0.00322	CcSEcCtD
Bosutinib—Decreased appetite—Ezetimibe—atherosclerosis	0.0004	0.00321	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.0004	0.0032	CcSEcCtD
Bosutinib—RPS6KB1—adipose tissue—atherosclerosis	0.000399	0.00308	CbGeAlD
Bosutinib—BTK—liver—atherosclerosis	0.000398	0.00307	CbGeAlD
Bosutinib—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000398	0.00318	CcSEcCtD
Bosutinib—Asthenia—Rosuvastatin—atherosclerosis	0.000397	0.00318	CcSEcCtD
Bosutinib—Oedema—Pravastatin—atherosclerosis	0.000397	0.00318	CcSEcCtD
Bosutinib—Anaphylactic shock—Pravastatin—atherosclerosis	0.000397	0.00318	CcSEcCtD
Bosutinib—Fatigue—Ezetimibe—atherosclerosis	0.000397	0.00318	CcSEcCtD
Bosutinib—LCK—adipose tissue—atherosclerosis	0.000397	0.00306	CbGeAlD
Bosutinib—FGR—adipose tissue—atherosclerosis	0.000397	0.00306	CbGeAlD
Bosutinib—AXL—adipose tissue—atherosclerosis	0.000395	0.00305	CbGeAlD
Bosutinib—Infection—Pravastatin—atherosclerosis	0.000394	0.00316	CcSEcCtD
Bosutinib—Pain—Ezetimibe—atherosclerosis	0.000394	0.00315	CcSEcCtD
Bosutinib—TNK2—liver—atherosclerosis	0.000392	0.00302	CbGeAlD
Bosutinib—Pruritus—Rosuvastatin—atherosclerosis	0.000392	0.00314	CcSEcCtD
Bosutinib—Skin disorder—Niacin—atherosclerosis	0.000392	0.00314	CcSEcCtD
Bosutinib—Dyspnoea—Simvastatin—atherosclerosis	0.000392	0.00314	CcSEcCtD
Bosutinib—Thrombocytopenia—Pravastatin—atherosclerosis	0.000389	0.00311	CcSEcCtD
Bosutinib—Feeling abnormal—Lovastatin—atherosclerosis	0.000387	0.0031	CcSEcCtD
Bosutinib—MAP4K2—liver—atherosclerosis	0.000387	0.00298	CbGeAlD
Bosutinib—Gastrointestinal pain—Lovastatin—atherosclerosis	0.000384	0.00308	CcSEcCtD
Bosutinib—Vandetanib—ALB—atherosclerosis	0.000382	0.176	CrCbGaD
Bosutinib—Decreased appetite—Simvastatin—atherosclerosis	0.000382	0.00306	CcSEcCtD
Bosutinib—STK3—liver—atherosclerosis	0.000381	0.00294	CbGeAlD
Bosutinib—SLK—adipose tissue—atherosclerosis	0.00038	0.00293	CbGeAlD
Bosutinib—Feeling abnormal—Ezetimibe—atherosclerosis	0.000379	0.00304	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.000379	0.00304	CcSEcCtD
Bosutinib—Diarrhoea—Rosuvastatin—atherosclerosis	0.000379	0.00304	CcSEcCtD
Bosutinib—Fatigue—Simvastatin—atherosclerosis	0.000379	0.00303	CcSEcCtD
Bosutinib—EPHB4—adipose tissue—atherosclerosis	0.000378	0.00291	CbGeAlD
Bosutinib—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000377	0.00302	CcSEcCtD
Bosutinib—ROCK1—liver—atherosclerosis	0.000376	0.0029	CbGeAlD
Bosutinib—CSF1R—connective tissue—atherosclerosis	0.000376	0.0029	CbGeAlD
Bosutinib—Pain—Simvastatin—atherosclerosis	0.000376	0.00301	CcSEcCtD
Bosutinib—STK10—cardiovascular system—atherosclerosis	0.000375	0.00289	CbGeAlD
Bosutinib—TAOK3—cardiovascular system—atherosclerosis	0.000374	0.00288	CbGeAlD
Bosutinib—Urticaria—Lovastatin—atherosclerosis	0.000373	0.00299	CcSEcCtD
Bosutinib—Body temperature increased—Lovastatin—atherosclerosis	0.000371	0.00297	CcSEcCtD
Bosutinib—Abdominal pain—Lovastatin—atherosclerosis	0.000371	0.00297	CcSEcCtD
Bosutinib—EPHA2—adipose tissue—atherosclerosis	0.00037	0.00286	CbGeAlD
Bosutinib—FYN—adipose tissue—atherosclerosis	0.00037	0.00285	CbGeAlD
Bosutinib—Musculoskeletal discomfort—Niacin—atherosclerosis	0.000367	0.00294	CcSEcCtD
Bosutinib—Dizziness—Rosuvastatin—atherosclerosis	0.000366	0.00293	CcSEcCtD
Bosutinib—Urticaria—Ezetimibe—atherosclerosis	0.000366	0.00293	CcSEcCtD
Bosutinib—BMPR2—liver—atherosclerosis	0.000366	0.00282	CbGeAlD
Bosutinib—SRC—cardiovascular system—atherosclerosis	0.000364	0.00281	CbGeAlD
Bosutinib—Body temperature increased—Ezetimibe—atherosclerosis	0.000364	0.00292	CcSEcCtD
Bosutinib—Abdominal pain—Ezetimibe—atherosclerosis	0.000364	0.00292	CcSEcCtD
Bosutinib—Gefitinib—ALB—atherosclerosis	0.000363	0.168	CrCbGaD
Bosutinib—STK36—liver—atherosclerosis	0.000363	0.0028	CbGeAlD
Bosutinib—Feeling abnormal—Simvastatin—atherosclerosis	0.000362	0.0029	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.000362	0.0029	CcSEcCtD
Bosutinib—MAP4K5—adipose tissue—atherosclerosis	0.000361	0.00279	CbGeAlD
Bosutinib—MAP3K3—adipose tissue—atherosclerosis	0.000361	0.00279	CbGeAlD
Bosutinib—Dyspnoea—Niacin—atherosclerosis	0.000359	0.00288	CcSEcCtD
Bosutinib—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000359	0.00288	CcSEcCtD
Bosutinib—MERTK—liver—atherosclerosis	0.000359	0.00276	CbGeAlD
Bosutinib—Dyspnoea—Pravastatin—atherosclerosis	0.000354	0.00284	CcSEcCtD
Bosutinib—MAP4K4—liver—atherosclerosis	0.000352	0.00271	CbGeAlD
Bosutinib—Decreased appetite—Niacin—atherosclerosis	0.000351	0.00281	CcSEcCtD
Bosutinib—NUAK2—liver—atherosclerosis	0.000349	0.00269	CbGeAlD
Bosutinib—BCR—liver—atherosclerosis	0.000349	0.00269	CbGeAlD
Bosutinib—Rash—Rosuvastatin—atherosclerosis	0.000349	0.0028	CcSEcCtD
Bosutinib—Dermatitis—Rosuvastatin—atherosclerosis	0.000349	0.0028	CcSEcCtD
Bosutinib—Urticaria—Simvastatin—atherosclerosis	0.000349	0.00279	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Niacin—atherosclerosis	0.000348	0.00279	CcSEcCtD
Bosutinib—Body temperature increased—Simvastatin—atherosclerosis	0.000347	0.00278	CcSEcCtD
Bosutinib—Abdominal pain—Simvastatin—atherosclerosis	0.000347	0.00278	CcSEcCtD
Bosutinib—Headache—Rosuvastatin—atherosclerosis	0.000347	0.00278	CcSEcCtD
Bosutinib—MAP3K12—liver—atherosclerosis	0.000347	0.00267	CbGeAlD
Bosutinib—Decreased appetite—Pravastatin—atherosclerosis	0.000345	0.00276	CcSEcCtD
Bosutinib—Pain—Niacin—atherosclerosis	0.000345	0.00276	CcSEcCtD
Bosutinib—Fatigue—Pravastatin—atherosclerosis	0.000342	0.00274	CcSEcCtD
Bosutinib—MAP2K1—liver—atherosclerosis	0.00034	0.00262	CbGeAlD
Bosutinib—STK35—liver—atherosclerosis	0.00034	0.00262	CbGeAlD
Bosutinib—Pain—Pravastatin—atherosclerosis	0.00034	0.00272	CcSEcCtD
Bosutinib—CSK—liver—atherosclerosis	0.000338	0.0026	CbGeAlD
Bosutinib—Asthenia—Lovastatin—atherosclerosis	0.000337	0.0027	CcSEcCtD
Bosutinib—CSNK1A1—liver—atherosclerosis	0.000336	0.00259	CbGeAlD
Bosutinib—MAP2K5—cardiovascular system—atherosclerosis	0.000335	0.00258	CbGeAlD
Bosutinib—YES1—adipose tissue—atherosclerosis	0.000334	0.00257	CbGeAlD
Bosutinib—HCK—liver—atherosclerosis	0.000333	0.00257	CbGeAlD
Bosutinib—CLK1—liver—atherosclerosis	0.000333	0.00257	CbGeAlD
Bosutinib—PDGFRB—connective tissue—atherosclerosis	0.000333	0.00257	CbGeAlD
Bosutinib—Pruritus—Lovastatin—atherosclerosis	0.000332	0.00266	CcSEcCtD
Bosutinib—ABL2—liver—atherosclerosis	0.000331	0.00255	CbGeAlD
Bosutinib—STK10—adipose tissue—atherosclerosis	0.000331	0.00255	CbGeAlD
Bosutinib—Asthenia—Ezetimibe—atherosclerosis	0.00033	0.00265	CcSEcCtD
Bosutinib—Gastrointestinal pain—Niacin—atherosclerosis	0.00033	0.00264	CcSEcCtD
Bosutinib—TAOK3—adipose tissue—atherosclerosis	0.000329	0.00254	CbGeAlD
Bosutinib—Nausea—Rosuvastatin—atherosclerosis	0.000329	0.00264	CcSEcCtD
Bosutinib—CAMK2G—liver—atherosclerosis	0.000327	0.00252	CbGeAlD
Bosutinib—BMP2K—liver—atherosclerosis	0.000327	0.00252	CbGeAlD
Bosutinib—Feeling abnormal—Pravastatin—atherosclerosis	0.000327	0.00262	CcSEcCtD
Bosutinib—CSF1R—cardiovascular system—atherosclerosis	0.000327	0.00252	CbGeAlD
Bosutinib—Pruritus—Ezetimibe—atherosclerosis	0.000326	0.00261	CcSEcCtD
Bosutinib—Gastrointestinal pain—Pravastatin—atherosclerosis	0.000325	0.0026	CcSEcCtD
Bosutinib—LRRK2—liver—atherosclerosis	0.000324	0.0025	CbGeAlD
Bosutinib—EGFR—liver—atherosclerosis	0.000323	0.00249	CbGeAlD
Bosutinib—Diarrhoea—Lovastatin—atherosclerosis	0.000321	0.00257	CcSEcCtD
Bosutinib—SRC—adipose tissue—atherosclerosis	0.000321	0.00247	CbGeAlD
Bosutinib—Urticaria—Niacin—atherosclerosis	0.00032	0.00257	CcSEcCtD
Bosutinib—Abdominal pain—Niacin—atherosclerosis	0.000319	0.00255	CcSEcCtD
Bosutinib—Body temperature increased—Niacin—atherosclerosis	0.000319	0.00255	CcSEcCtD
Bosutinib—PTK2B—liver—atherosclerosis	0.000316	0.00244	CbGeAlD
Bosutinib—Urticaria—Pravastatin—atherosclerosis	0.000315	0.00253	CcSEcCtD
Bosutinib—Asthenia—Simvastatin—atherosclerosis	0.000315	0.00252	CcSEcCtD
Bosutinib—Diarrhoea—Ezetimibe—atherosclerosis	0.000315	0.00252	CcSEcCtD
Bosutinib—Body temperature increased—Pravastatin—atherosclerosis	0.000314	0.00251	CcSEcCtD
Bosutinib—Abdominal pain—Pravastatin—atherosclerosis	0.000314	0.00251	CcSEcCtD
Bosutinib—CSNK1E—liver—atherosclerosis	0.000311	0.0024	CbGeAlD
Bosutinib—Pruritus—Simvastatin—atherosclerosis	0.000311	0.00249	CcSEcCtD
Bosutinib—Dizziness—Lovastatin—atherosclerosis	0.00031	0.00249	CcSEcCtD
Bosutinib—SIK1—liver—atherosclerosis	0.000306	0.00236	CbGeAlD
Bosutinib—IRAK4—liver—atherosclerosis	0.000306	0.00236	CbGeAlD
Bosutinib—Dizziness—Ezetimibe—atherosclerosis	0.000305	0.00244	CcSEcCtD
Bosutinib—Diarrhoea—Simvastatin—atherosclerosis	0.0003	0.00241	CcSEcCtD
Bosutinib—ERBB3—liver—atherosclerosis	0.0003	0.00231	CbGeAlD
Bosutinib—MAP2K2—liver—atherosclerosis	0.000299	0.00231	CbGeAlD
Bosutinib—ULK3—liver—atherosclerosis	0.000299	0.00231	CbGeAlD
Bosutinib—Vomiting—Lovastatin—atherosclerosis	0.000299	0.00239	CcSEcCtD
Bosutinib—MAP3K2—liver—atherosclerosis	0.000297	0.00229	CbGeAlD
Bosutinib—ABL1—connective tissue—atherosclerosis	0.000297	0.00229	CbGeAlD
Bosutinib—Rash—Lovastatin—atherosclerosis	0.000296	0.00237	CcSEcCtD
Bosutinib—Dermatitis—Lovastatin—atherosclerosis	0.000296	0.00237	CcSEcCtD
Bosutinib—MAP2K5—adipose tissue—atherosclerosis	0.000295	0.00228	CbGeAlD
Bosutinib—MAP3K7—liver—atherosclerosis	0.000294	0.00227	CbGeAlD
Bosutinib—Headache—Lovastatin—atherosclerosis	0.000294	0.00236	CcSEcCtD
Bosutinib—Vomiting—Ezetimibe—atherosclerosis	0.000293	0.00235	CcSEcCtD
Bosutinib—PTK2—liver—atherosclerosis	0.000291	0.00224	CbGeAlD
Bosutinib—TBK1—liver—atherosclerosis	0.000291	0.00224	CbGeAlD
Bosutinib—Dizziness—Simvastatin—atherosclerosis	0.00029	0.00233	CcSEcCtD
Bosutinib—Rash—Ezetimibe—atherosclerosis	0.00029	0.00233	CcSEcCtD
Bosutinib—Dermatitis—Ezetimibe—atherosclerosis	0.00029	0.00232	CcSEcCtD
Bosutinib—PDGFRB—cardiovascular system—atherosclerosis	0.00029	0.00223	CbGeAlD
Bosutinib—Asthenia—Niacin—atherosclerosis	0.000289	0.00232	CcSEcCtD
Bosutinib—Headache—Ezetimibe—atherosclerosis	0.000288	0.00231	CcSEcCtD
Bosutinib—CSF1R—adipose tissue—atherosclerosis	0.000288	0.00222	CbGeAlD
Bosutinib—Pruritus—Niacin—atherosclerosis	0.000285	0.00229	CcSEcCtD
Bosutinib—IRAK1—liver—atherosclerosis	0.000285	0.0022	CbGeAlD
Bosutinib—Asthenia—Pravastatin—atherosclerosis	0.000285	0.00228	CcSEcCtD
Bosutinib—Pruritus—Pravastatin—atherosclerosis	0.000281	0.00225	CcSEcCtD
Bosutinib—RPS6KB1—liver—atherosclerosis	0.00028	0.00216	CbGeAlD
Bosutinib—Vomiting—Simvastatin—atherosclerosis	0.000279	0.00224	CcSEcCtD
Bosutinib—Nausea—Lovastatin—atherosclerosis	0.000279	0.00223	CcSEcCtD
Bosutinib—LCK—liver—atherosclerosis	0.000278	0.00214	CbGeAlD
Bosutinib—FGR—liver—atherosclerosis	0.000278	0.00214	CbGeAlD
Bosutinib—AXL—liver—atherosclerosis	0.000277	0.00214	CbGeAlD
Bosutinib—Rash—Simvastatin—atherosclerosis	0.000277	0.00222	CcSEcCtD
Bosutinib—Dermatitis—Simvastatin—atherosclerosis	0.000277	0.00222	CcSEcCtD
Bosutinib—Diarrhoea—Niacin—atherosclerosis	0.000276	0.00221	CcSEcCtD
Bosutinib—Headache—Simvastatin—atherosclerosis	0.000275	0.0022	CcSEcCtD
Bosutinib—Nausea—Ezetimibe—atherosclerosis	0.000274	0.00219	CcSEcCtD
Bosutinib—Diarrhoea—Pravastatin—atherosclerosis	0.000272	0.00218	CcSEcCtD
Bosutinib—SLK—liver—atherosclerosis	0.000267	0.00206	CbGeAlD
Bosutinib—Dizziness—Niacin—atherosclerosis	0.000267	0.00214	CcSEcCtD
Bosutinib—EPHB4—liver—atherosclerosis	0.000265	0.00204	CbGeAlD
Bosutinib—Dizziness—Pravastatin—atherosclerosis	0.000263	0.0021	CcSEcCtD
Bosutinib—Nausea—Simvastatin—atherosclerosis	0.000261	0.00209	CcSEcCtD
Bosutinib—EPHA2—liver—atherosclerosis	0.00026	0.002	CbGeAlD
Bosutinib—FYN—liver—atherosclerosis	0.000259	0.002	CbGeAlD
Bosutinib—ABL1—cardiovascular system—atherosclerosis	0.000258	0.00199	CbGeAlD
Bosutinib—Vomiting—Niacin—atherosclerosis	0.000256	0.00205	CcSEcCtD
Bosutinib—PDGFRB—adipose tissue—atherosclerosis	0.000256	0.00197	CbGeAlD
Bosutinib—Rash—Niacin—atherosclerosis	0.000254	0.00204	CcSEcCtD
Bosutinib—Dermatitis—Niacin—atherosclerosis	0.000254	0.00203	CcSEcCtD
Bosutinib—MAP3K3—liver—atherosclerosis	0.000253	0.00195	CbGeAlD
Bosutinib—MAP4K5—liver—atherosclerosis	0.000253	0.00195	CbGeAlD
Bosutinib—Headache—Niacin—atherosclerosis	0.000253	0.00202	CcSEcCtD
Bosutinib—Vomiting—Pravastatin—atherosclerosis	0.000252	0.00202	CcSEcCtD
Bosutinib—Rash—Pravastatin—atherosclerosis	0.00025	0.00201	CcSEcCtD
Bosutinib—Dermatitis—Pravastatin—atherosclerosis	0.00025	0.002	CcSEcCtD
Bosutinib—Headache—Pravastatin—atherosclerosis	0.000249	0.00199	CcSEcCtD
Bosutinib—Nausea—Niacin—atherosclerosis	0.00024	0.00192	CcSEcCtD
Bosutinib—Nausea—Pravastatin—atherosclerosis	0.000236	0.00189	CcSEcCtD
Bosutinib—YES1—liver—atherosclerosis	0.000234	0.0018	CbGeAlD
Bosutinib—STK10—liver—atherosclerosis	0.000232	0.00179	CbGeAlD
Bosutinib—TAOK3—liver—atherosclerosis	0.000231	0.00178	CbGeAlD
Bosutinib—ABL1—adipose tissue—atherosclerosis	0.000228	0.00176	CbGeAlD
Bosutinib—SRC—liver—atherosclerosis	0.000225	0.00174	CbGeAlD
Bosutinib—MAP2K5—liver—atherosclerosis	0.000207	0.0016	CbGeAlD
Bosutinib—CSF1R—liver—atherosclerosis	0.000202	0.00156	CbGeAlD
Bosutinib—ABCB1—blood vessel—atherosclerosis	0.00018	0.00139	CbGeAlD
Bosutinib—PDGFRB—liver—atherosclerosis	0.000179	0.00138	CbGeAlD
Bosutinib—ABL1—liver—atherosclerosis	0.00016	0.00123	CbGeAlD
Bosutinib—ABCB1—cardiovascular system—atherosclerosis	8.04e-05	0.000619	CbGeAlD
Bosutinib—ABCB1—adipose tissue—atherosclerosis	7.09e-05	0.000546	CbGeAlD
Bosutinib—CYP3A4—liver—atherosclerosis	7.02e-05	0.000541	CbGeAlD
Bosutinib—ABCB1—liver—atherosclerosis	4.97e-05	0.000383	CbGeAlD
Bosutinib—SRC—Signaling Pathways—CAV1—atherosclerosis	1.3e-06	5.09e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PLA2G1B—atherosclerosis	1.3e-06	5.08e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—MAPK3—atherosclerosis	1.3e-06	5.08e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—APOA1—atherosclerosis	1.3e-06	5.08e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—STAT3—atherosclerosis	1.3e-06	5.07e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—IL1B—atherosclerosis	1.3e-06	5.06e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CCL2—atherosclerosis	1.29e-06	5.06e-06	CbGpPWpGaD
Bosutinib—YES1—Immune System—AKT1—atherosclerosis	1.29e-06	5.06e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—MAPK3—atherosclerosis	1.29e-06	5.05e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—NFKB1—atherosclerosis	1.29e-06	5.04e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—PTGS2—atherosclerosis	1.29e-06	5.03e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—STAT3—atherosclerosis	1.27e-06	4.98e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—IGF1—atherosclerosis	1.27e-06	4.97e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—INS—atherosclerosis	1.27e-06	4.96e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—MAPK8—atherosclerosis	1.27e-06	4.96e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—TGFB1—atherosclerosis	1.26e-06	4.93e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—CXCL8—atherosclerosis	1.26e-06	4.92e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—MAPK3—atherosclerosis	1.26e-06	4.91e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ALOX5—atherosclerosis	1.26e-06	4.91e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—ESR1—atherosclerosis	1.25e-06	4.9e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—TGFB1—atherosclerosis	1.25e-06	4.9e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—IL6—atherosclerosis	1.25e-06	4.89e-06	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—AKT1—atherosclerosis	1.25e-06	4.89e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CCL2—atherosclerosis	1.25e-06	4.88e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—VEGFA—atherosclerosis	1.24e-06	4.86e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—MAPK3—atherosclerosis	1.24e-06	4.85e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—F2—atherosclerosis	1.24e-06	4.84e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—STAT3—atherosclerosis	1.23e-06	4.81e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—CXCL8—atherosclerosis	1.23e-06	4.8e-06	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—AKT1—atherosclerosis	1.23e-06	4.8e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—STAT3—atherosclerosis	1.23e-06	4.8e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—IGF1—atherosclerosis	1.23e-06	4.79e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—TGFB1—atherosclerosis	1.22e-06	4.77e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—MAPK3—atherosclerosis	1.22e-06	4.75e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—HMOX1—atherosclerosis	1.21e-06	4.74e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—NFKB1—atherosclerosis	1.21e-06	4.72e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—SERPINE1—atherosclerosis	1.21e-06	4.72e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—CXCL8—atherosclerosis	1.2e-06	4.7e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—TGFB1—atherosclerosis	1.2e-06	4.7e-06	CbGpPWpGaD
Bosutinib—SRC—Innate Immune System—AKT1—atherosclerosis	1.2e-06	4.7e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—IL6—atherosclerosis	1.2e-06	4.68e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—MAPK8—atherosclerosis	1.19e-06	4.64e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PIK3CG—atherosclerosis	1.19e-06	4.64e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—CXCL8—atherosclerosis	1.18e-06	4.63e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—CXCL8—atherosclerosis	1.18e-06	4.61e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—MAPK3—atherosclerosis	1.18e-06	4.6e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—STAT3—atherosclerosis	1.18e-06	4.59e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—MAPK3—atherosclerosis	1.17e-06	4.58e-06	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—IL6—atherosclerosis	1.17e-06	4.58e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—VEGFA—atherosclerosis	1.17e-06	4.58e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—SERPINE1—atherosclerosis	1.16e-06	4.55e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—APOB—atherosclerosis	1.16e-06	4.54e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—STAT3—atherosclerosis	1.16e-06	4.53e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—AKT1—atherosclerosis	1.15e-06	4.52e-06	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—IL6—atherosclerosis	1.15e-06	4.51e-06	CbGpPWpGaD
Bosutinib—SRC—Adaptive Immune System—AKT1—atherosclerosis	1.15e-06	4.51e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—NOS3—atherosclerosis	1.15e-06	4.51e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—TGFB1—atherosclerosis	1.14e-06	4.46e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—MMP9—atherosclerosis	1.14e-06	4.45e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—STAT3—atherosclerosis	1.13e-06	4.43e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—GSTM1—atherosclerosis	1.13e-06	4.42e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—NFKB1—atherosclerosis	1.13e-06	4.41e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—NAMPT—atherosclerosis	1.13e-06	4.4e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—MAPK3—atherosclerosis	1.12e-06	4.39e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—INS—atherosclerosis	1.12e-06	4.39e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—IL6—atherosclerosis	1.12e-06	4.38e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—LIPC—atherosclerosis	1.12e-06	4.38e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—APOC3—atherosclerosis	1.11e-06	4.35e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—IL6—atherosclerosis	1.11e-06	4.35e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—NOS3—atherosclerosis	1.11e-06	4.35e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—MMP9—atherosclerosis	1.11e-06	4.35e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—LPL—atherosclerosis	1.11e-06	4.34e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—MAPK8—atherosclerosis	1.11e-06	4.33e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—MAPK3—atherosclerosis	1.11e-06	4.33e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—LDLR—atherosclerosis	1.11e-06	4.32e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—AKT1—atherosclerosis	1.1e-06	4.32e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CCL2—atherosclerosis	1.1e-06	4.32e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—NFKB1—atherosclerosis	1.1e-06	4.3e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—IL6—atherosclerosis	1.09e-06	4.28e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—TGFB1—atherosclerosis	1.09e-06	4.26e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—MMP9—atherosclerosis	1.09e-06	4.25e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—STAT3—atherosclerosis	1.09e-06	4.25e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IGF1—atherosclerosis	1.09e-06	4.24e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—MAPK3—atherosclerosis	1.08e-06	4.23e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—GPX1—atherosclerosis	1.08e-06	4.23e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—MAPK8—atherosclerosis	1.08e-06	4.23e-06	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—AKT1—atherosclerosis	1.08e-06	4.22e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CETP—atherosclerosis	1.08e-06	4.22e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—NFKB1—atherosclerosis	1.08e-06	4.21e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—TGFB1—atherosclerosis	1.07e-06	4.2e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—MMP9—atherosclerosis	1.07e-06	4.19e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—IL6—atherosclerosis	1.07e-06	4.19e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—IL6—atherosclerosis	1.07e-06	4.19e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—IL6—atherosclerosis	1.07e-06	4.17e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—MMP9—atherosclerosis	1.07e-06	4.17e-06	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—AKT1—atherosclerosis	1.06e-06	4.16e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—NFKB1—atherosclerosis	1.06e-06	4.14e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—MAPK8—atherosclerosis	1.06e-06	4.14e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—NFKB1—atherosclerosis	1.05e-06	4.12e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—CD36—atherosclerosis	1.05e-06	4.12e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—TGFB1—atherosclerosis	1.05e-06	4.1e-06	CbGpPWpGaD
Bosutinib—LYN—Immune System—IL6—atherosclerosis	1.05e-06	4.09e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—MAPK8—atherosclerosis	1.04e-06	4.07e-06	CbGpPWpGaD
Bosutinib—ABL1—Immune System—IL6—atherosclerosis	1.04e-06	4.07e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—MAPK3—atherosclerosis	1.04e-06	4.06e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—MAPK8—atherosclerosis	1.04e-06	4.05e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—SCARB1—atherosclerosis	1.03e-06	4.04e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—AKT1—atherosclerosis	1.03e-06	4.04e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—IL6—atherosclerosis	1.03e-06	4.04e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—SERPINE1—atherosclerosis	1.03e-06	4.03e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—IL6—atherosclerosis	1.03e-06	4.02e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—AKT1—atherosclerosis	1.03e-06	4.01e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—IL6—atherosclerosis	1.02e-06	4e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CXCL8—atherosclerosis	1.02e-06	4e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—VEGFA—atherosclerosis	1.02e-06	4e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—STAT3—atherosclerosis	1.01e-06	3.96e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—IL6—atherosclerosis	1.01e-06	3.95e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—AKT1—atherosclerosis	1.01e-06	3.95e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—STAT3—atherosclerosis	1e-06	3.92e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—MTHFR—atherosclerosis	9.98e-07	3.9e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—VEGFA—atherosclerosis	9.98e-07	3.9e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—AKT1—atherosclerosis	9.88e-07	3.86e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—AKT1—atherosclerosis	9.88e-07	3.86e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—STAT3—atherosclerosis	9.88e-07	3.86e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CXCL8—atherosclerosis	9.86e-07	3.86e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—IL6—atherosclerosis	9.86e-07	3.85e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—AKT1—atherosclerosis	9.85e-07	3.85e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—NOS3—atherosclerosis	9.84e-07	3.85e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PPARA—atherosclerosis	9.79e-07	3.83e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—VEGFA—atherosclerosis	9.77e-07	3.82e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—HMGCR—atherosclerosis	9.77e-07	3.82e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—IL6—atherosclerosis	9.73e-07	3.8e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—STAT3—atherosclerosis	9.67e-07	3.78e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—MAPK3—atherosclerosis	9.67e-07	3.78e-06	CbGpPWpGaD
Bosutinib—LYN—Immune System—AKT1—atherosclerosis	9.64e-07	3.77e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—VEGFA—atherosclerosis	9.62e-07	3.76e-06	CbGpPWpGaD
Bosutinib—ABL1—Immune System—AKT1—atherosclerosis	9.6e-07	3.75e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—MAPK3—atherosclerosis	9.58e-07	3.74e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—VEGFA—atherosclerosis	9.57e-07	3.74e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—AKT1—atherosclerosis	9.52e-07	3.72e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—STAT3—atherosclerosis	9.52e-07	3.72e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—IL6—atherosclerosis	9.5e-07	3.71e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—AKT1—atherosclerosis	9.49e-07	3.71e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—AGT—atherosclerosis	9.49e-07	3.71e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—STAT3—atherosclerosis	9.47e-07	3.7e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—IL6—atherosclerosis	9.45e-07	3.69e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—AKT1—atherosclerosis	9.44e-07	3.69e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—MAPK3—atherosclerosis	9.44e-07	3.69e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—TGFB1—atherosclerosis	9.39e-07	3.67e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—AKT1—atherosclerosis	9.32e-07	3.64e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—APOE—atherosclerosis	9.29e-07	3.63e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—TGFB1—atherosclerosis	9.29e-07	3.63e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MMP9—atherosclerosis	9.25e-07	3.62e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—MAPK3—atherosclerosis	9.24e-07	3.61e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—CAV1—atherosclerosis	9.21e-07	3.6e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—IL6—atherosclerosis	9.19e-07	3.59e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—APOA1—atherosclerosis	9.19e-07	3.59e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—TGFB1—atherosclerosis	9.16e-07	3.58e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—NFKB1—atherosclerosis	9.16e-07	3.58e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—MAPK3—atherosclerosis	9.1e-07	3.56e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—AKT1—atherosclerosis	9.09e-07	3.56e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—IL6—atherosclerosis	9.06e-07	3.54e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—MAPK3—atherosclerosis	9.05e-07	3.54e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MAPK8—atherosclerosis	9e-07	3.52e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—AKT1—atherosclerosis	8.98e-07	3.51e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—TGFB1—atherosclerosis	8.97e-07	3.51e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MMP9—atherosclerosis	8.92e-07	3.49e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—IL6—atherosclerosis	8.89e-07	3.48e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—TGFB1—atherosclerosis	8.83e-07	3.45e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—NFKB1—atherosclerosis	8.82e-07	3.45e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—TGFB1—atherosclerosis	8.78e-07	3.43e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—AKT1—atherosclerosis	8.76e-07	3.43e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CXCL8—atherosclerosis	8.73e-07	3.41e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—AKT1—atherosclerosis	8.72e-07	3.41e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ABCA1—atherosclerosis	8.71e-07	3.4e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MAPK8—atherosclerosis	8.67e-07	3.39e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—IL6—atherosclerosis	8.6e-07	3.36e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—IL6—atherosclerosis	8.57e-07	3.35e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—AKT1—atherosclerosis	8.48e-07	3.31e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PIK3CG—atherosclerosis	8.39e-07	3.28e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—AKT1—atherosclerosis	8.36e-07	3.27e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—VEGFA—atherosclerosis	8.31e-07	3.25e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—STAT3—atherosclerosis	8.23e-07	3.22e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—IL6—atherosclerosis	8.21e-07	3.21e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—AKT1—atherosclerosis	8.2e-07	3.21e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PPARG—atherosclerosis	8.1e-07	3.17e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—IL6—atherosclerosis	8.09e-07	3.16e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—VEGFA—atherosclerosis	8.01e-07	3.13e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—INS—atherosclerosis	7.94e-07	3.1e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—AKT1—atherosclerosis	7.93e-07	3.1e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—STAT3—atherosclerosis	7.93e-07	3.1e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—IL6—atherosclerosis	7.91e-07	3.09e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—AKT1—atherosclerosis	7.9e-07	3.09e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MMP9—atherosclerosis	7.9e-07	3.09e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MAPK3—atherosclerosis	7.86e-07	3.07e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—NFKB1—atherosclerosis	7.81e-07	3.05e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MAPK8—atherosclerosis	7.68e-07	3e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—TGFB1—atherosclerosis	7.63e-07	2.98e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—IL6—atherosclerosis	7.58e-07	2.97e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MAPK3—atherosclerosis	7.58e-07	2.96e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—AKT1—atherosclerosis	7.57e-07	2.96e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—HMOX1—atherosclerosis	7.47e-07	2.92e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—AKT1—atherosclerosis	7.47e-07	2.92e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—TGFB1—atherosclerosis	7.35e-07	2.87e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—AKT1—atherosclerosis	7.3e-07	2.85e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—ALB—atherosclerosis	7.28e-07	2.85e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—APOB—atherosclerosis	7.15e-07	2.8e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—VEGFA—atherosclerosis	7.09e-07	2.77e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—IL6—atherosclerosis	7.07e-07	2.77e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—STAT3—atherosclerosis	7.02e-07	2.74e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—IL6—atherosclerosis	7e-07	2.74e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—AKT1—atherosclerosis	7e-07	2.74e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—NOS3—atherosclerosis	6.96e-07	2.72e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GSTM1—atherosclerosis	6.96e-07	2.72e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—IL6—atherosclerosis	6.9e-07	2.7e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—LPL—atherosclerosis	6.83e-07	2.67e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—IL6—atherosclerosis	6.76e-07	2.64e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MAPK3—atherosclerosis	6.71e-07	2.62e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GPX1—atherosclerosis	6.66e-07	2.61e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—IL6—atherosclerosis	6.65e-07	2.6e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—IL6—atherosclerosis	6.62e-07	2.59e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—AKT1—atherosclerosis	6.52e-07	2.55e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—TGFB1—atherosclerosis	6.51e-07	2.54e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CD36—atherosclerosis	6.49e-07	2.54e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—AKT1—atherosclerosis	6.46e-07	2.53e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PTGS2—atherosclerosis	6.37e-07	2.49e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—AKT1—atherosclerosis	6.37e-07	2.49e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—AKT1—atherosclerosis	6.23e-07	2.44e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—MTHFR—atherosclerosis	6.15e-07	2.4e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—AKT1—atherosclerosis	6.14e-07	2.4e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—AKT1—atherosclerosis	6.1e-07	2.39e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PPARA—atherosclerosis	6.03e-07	2.36e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—AGT—atherosclerosis	5.84e-07	2.29e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—IL6—atherosclerosis	5.75e-07	2.25e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—APOE—atherosclerosis	5.73e-07	2.24e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CAV1—atherosclerosis	5.67e-07	2.22e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—APOA1—atherosclerosis	5.66e-07	2.21e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—IL6—atherosclerosis	5.54e-07	2.17e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—AKT1—atherosclerosis	5.3e-07	2.07e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PIK3CG—atherosclerosis	5.17e-07	2.02e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—AKT1—atherosclerosis	5.11e-07	2e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PPARG—atherosclerosis	4.99e-07	1.95e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IL6—atherosclerosis	4.9e-07	1.92e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—INS—atherosclerosis	4.89e-07	1.91e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—AKT1—atherosclerosis	4.52e-07	1.77e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ALB—atherosclerosis	4.48e-07	1.75e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—NOS3—atherosclerosis	4.29e-07	1.68e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PTGS2—atherosclerosis	3.92e-07	1.53e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—AKT1—atherosclerosis	3.2e-07	1.25e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—AKT1—atherosclerosis	1.97e-07	7.71e-07	CbGpPWpGaD
